YouTube video by REPO4EU

A groundbreaking clinical trial has been launched in the UK to accelerate the development of new treatments for Alzheimer's disease. The AD-SMART study, led by the UK Dementia Research Institute and Alzheimer's Research UK, will simultaneously test multiple repurposed medications, starting with metformin (used for type 2 diabetes) and atomoxetine (used for ADHD). These drugs were selected by an international panel of experts for their potential to reduce brain inflammation, a key factor in neurodegeneration. The trial employs a multi-arm, multi-stage platform approach, allowing for rapid replacement of ineffective treatments with new ones, a method previously successful in cancer and motor neurone disease research. Angela Bucksey, a 67-year-old Cambridgeshire resident diagnosed with Alzheimer's in January, is the first participant in the trial. She expressed feeling empowered by joining the study, stating, 'at least you are doing something' rather than passively accepting the diagnosis. Prime Minister Andy Burnham, whose father recently died from Alzheimer's, praised the initiative, emphasizing the need for 'cutting-edge treatments' to reach patients quickly. The study aims to evaluate whether these medications can improve cognitive function and daily living abilities, which are critical concerns for patients and caregivers. Approximately 1,200 participants with mild to moderate Alzheimer's will be recruited across 30+ UK sites, with results expected by 2030. Regular cognitive assessments will be conducted to measure treatment effectiveness. Dr. Sheona Scales of Alzheimer's Research UK stressed that 'time is precious' for those living with the disease, highlighting the urgent need for additional treatment options. The trial represents a significant shift from traditional single-drug, single-trial approaches that often take a decade or more to yield results. By leveraging advances from other medical fields, researchers aim to dramatically shorten the timeline for developing effective Alzheimer's therapies. The study's innovative methodology could potentially transform how dementia treatments are developed and tested globally.

Every year, people suffer severe brain injuries that lead to prolonged disorders of consciousness (DOC), such as a vegetative or minimally conscious state. These conditions can last for years, placing...

Excited to share that our lab at the Broad Institute has received an NIH Director's Transformative Research Award from the NIH Common Fund's High-Risk, High-Reward Research Program!  Our project, Enc...

Modified medication targets the cells implicated in the condition’s tell-tale lesions.

Explore breakthroughs in biotechnology and AI for combating resistant Pneumococcus. Discover how AI screens drugs to tackle Pneumococcus effectively.

adalimumab idiopathic multicentric Castleman disease machine learning: the interesting part is not that AI “found a cure.” It is that a model-generated drug ranking became worth taking seriously only...

A common blood pressure drug is making cancer therapy far more powerful. Telmisartan, prescribed to millions for hypertension, enhances olaparib's anticancer … #Cancertherapy #Clinicaltrials #Drugrepurposing #Immunotherapy #Olaparib

When most of us hear “growth hormone,” we think of childhood, with bones lengthening, bodies developing, and the remarkable biological machinery that turns a small child into an adult. Growth hormone,...

This lecture will discuss the CURE ID website and mobile app, and how it can serve as an important real-world data tool to help identify treatments for diseases that don’t have good, approved treatmen...

H.M. Pharma Consultancy is a service provider, but we are scientists at heart - and database builders. This allows us to see opportunities that others miss.

Genelife, Clinical Research, GCP, Medical Device, Patient Recruitment, Asthma, Oncology, Ophthalmology, Clinical Trials, Cancer, tuberculosis